Insilico teams-up with Intel to identify disease progression risk

Latest articles

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Humanpeople raising £700k for AI preventative health platform

Digital preventative health platform combines blood, DNA and microbiome testing to power up your healthspan with highly personalised supplements. DISCLOSURE: Longevity.Technology (a brand of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Click the globe for translations.

Insilico’s new COVIDomic platform combines cutting-edge AI with Intel Xeon processors and could turn the pandemic tide.

Insilico have been rather busy lately; a couple of months ago they announced a partnership with Arctoris, then Deep Longevity, their spin-out, exited stealth with an HLI collaboration, before being swiftly snapped up by Regent Pacific.

Longevity.Technology: This AI/Intel platform will leverage vast amounts of data in the search for therapies for COVID-19. However, serious diseases are life-limiting, and being able to chart and halt their progression will pay dividends for Longevity. As the reservoirs of omics data grow, the better chance we have of finding therapy solutions that will prolong both lifespan and healthspan.

Today, Insilico has announced that it is launching an AI-powered platform – COVIDomic – to support COVID-19 research worldwide. COVIDomic is a cloud-based platform that uses AI approaches and Intel architecture to identify risk factors associated with severe disease progression.

COVIDomic will be deployed for both basic and clinical research in COVID-19. A foundational technology, COVIDomic is built using massive multi-omics datasets, sophisticated dimensionality reduction algorithms and deep learning systems; this amount of computing will rely on Intel Xeon processors.

Insilico’s new COVIDomic platform. Source: Insilico

The cloud-based platform uses AI approaches to identify risk factors associated with severe disease progression. A researcher can upload wide combinations of patient data, including viral and human genomes, rich metadata (describing patient’s lifestyle, co-morbid disorders and biological age), results of blood tests; and even transcriptomic sequencing of lung fluid or nasal swabs (to identify changes in microbial communities).

As a result, the platform identifies the minimum number of relevant features that could be used to define severe disease progression for a given population.

COVIDomic will enable scientists to use anonymised patient data to integrate with a variety of existing data sets. Bioinformatics and Artificial Intelligence (AI) tools can then be applied in many ways, starting with better stratifying of COVID-19 patients, understanding the disease trajectory, and identifying relevant disease pathways and targets.

 


The development team is inviting scientists globally to contribute to the development of the system and engage in active research collaborations.

 


 

“COVIDomic is an open access tool to stratify risk and severity from multimodal data sets,
including multi-omics data. Insilico Medicine’s AI-driven generative biology approach is a unique offering in the marketplace. We are part of many COVID-19 consortiums and collaborations but COVIDomic is a system that will help scientists and researchers alike to predict the severity of the disease”, said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “By predicting outcomes, clinicians can establish protocols and treatments we hope will reduce the severity and mortality of infection.”

“Analyzing massive amounts of data – quickly – across geographies and data sets is essential for gaining insights into how the novel coronavirus affects people across the world,” noted Rick Echevarria, Intel Vice President, Sales, Marketing, and Communications Group. “Intel computing power enables AI that can help researchers in the fight against COVID-19. We hope that by sharing our expertise, resources and technology we can help accelerate research across diverse geographies and with companies such as Insilico Medicine.”

Image credit: Ascannio / Shutterstock
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Humanpeople raising £700k for AI preventative health platform

Digital preventative health platform combines blood, DNA and microbiome testing to power up your healthspan with highly personalised supplements. DISCLOSURE: Longevity.Technology (a brand of...

Printers that can now print DNA

DNA Script obtains CE Mark for SYNTAX DNA printing platform. DNA Script, a leader in Enzymatic DNA Synthesis (EDS), announced the CE marking of its SYNTAX System, the...

A brain fitbit that can spot Alzheimer’s with up to 94% accuracy

Altoida raising new financing for augmented reality cognitive assessment platform that dramatically improves early detection of Alzheimer’s and other neurodegenerative diseases. Earlier this year, AR-powered...

Insilico starts human trial with AI-discovered drug

First human dosed with AI-discovered novel molecule based on an AI-discovered novel target. Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, has announced that the...

    Subscribe to our newsletter